130 related articles for article (PubMed ID: 37198894)
21. Methotrexate re-challenge for recurrent primary central nervous system lymphoma.
Pentsova E; Deangelis LM; Omuro A
J Neurooncol; 2014 Mar; 117(1):161-5. PubMed ID: 24481997
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.
Makino K; Nakamura H; Hide T; Kuroda J; Yano S; Kuratsu J
Int J Clin Oncol; 2015 Feb; 20(1):29-34. PubMed ID: 24722885
[TBL] [Abstract][Full Text] [Related]
23. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
[TBL] [Abstract][Full Text] [Related]
24. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
Joerger M; Huitema AD; Krähenbühl S; Schellens JH; Cerny T; Reni M; Zucca E; Cavalli F; Ferreri AJ
Br J Cancer; 2010 Feb; 102(4):673-7. PubMed ID: 20125159
[TBL] [Abstract][Full Text] [Related]
25. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
26. High-dose methotrexate dosing strategy in primary central nervous system lymphoma.
Wang A; Cirrone F; De Los Reyes FA; Papadopoulos J; Saint Fleur-Lominy S; Xiang E
Leuk Lymphoma; 2022 Jun; 63(6):1348-1355. PubMed ID: 35120432
[TBL] [Abstract][Full Text] [Related]
27. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
[TBL] [Abstract][Full Text] [Related]
28. Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution.
Aoki H; Ogura R; Tsukamoto Y; Okada M; Natsumeda M; Isogawa M; Yoshida S; Fujii Y
Neurol Med Chir (Tokyo); 2013; 53(11):797-804. PubMed ID: 24162244
[TBL] [Abstract][Full Text] [Related]
29. Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study.
Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L
Int J Clin Oncol; 2021 Oct; 26(10):1805-1811. PubMed ID: 34236556
[TBL] [Abstract][Full Text] [Related]
30. Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
Kansara R; Shenkier TN; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D
Am J Hematol; 2015 Dec; 90(12):1149-54. PubMed ID: 26414492
[TBL] [Abstract][Full Text] [Related]
31. High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).
Salamoon M; Hussein T; Kenj M; Bachour M
Med Oncol; 2013 Dec; 30(4):690. PubMed ID: 23959450
[TBL] [Abstract][Full Text] [Related]
32. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients.
Sarid N; Bokstein F; Blumenthal DT; Weiss-Meilik A; Gibstein L; Avivi I; Perry C; Ram R
J Neurooncol; 2021 Jan; 151(2):211-220. PubMed ID: 33099747
[TBL] [Abstract][Full Text] [Related]
33. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma.
Pai MP; Debacker KC; Derstine B; Sullivan J; Su GL; Wang SC
Pharmacotherapy; 2020 Apr; 40(4):308-319. PubMed ID: 32090349
[TBL] [Abstract][Full Text] [Related]
35. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
36. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
[TBL] [Abstract][Full Text] [Related]
37. A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma.
Uhm JE; Kim KH; Yi SY; Chang MH; Park KW; Kong DS; Lee JI; Nam DH; Park W; Lim do H; Kim SJ; Kim K; Ko YH; Kim WS
Leuk Lymphoma; 2009 Jul; 50(7):1110-8. PubMed ID: 19557631
[TBL] [Abstract][Full Text] [Related]
38. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
[TBL] [Abstract][Full Text] [Related]
39. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
Plotkin SR; Betensky RA; Hochberg FH; Grossman SA; Lesser GJ; Nabors LB; Chon B; Batchelor TT
Clin Cancer Res; 2004 Sep; 10(17):5643-6. PubMed ID: 15355887
[TBL] [Abstract][Full Text] [Related]
40. The role of additional radiotherapy for primary central nervous system lymphoma.
Zacher J; Kasenda B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009211. PubMed ID: 24931518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]